<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02655471</url>
  </required_header>
  <id_info>
    <org_study_id>65384</org_study_id>
    <nct_id>NCT02655471</nct_id>
  </id_info>
  <brief_title>Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection</brief_title>
  <official_title>Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Peruana Cayetano Heredia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Peruana Cayetano Heredia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study of intervention in a group of patients with tropical spastic
      paraparesis/ myelopathy to evaluate virologic and clinical response of raltegravir plus
      zidovudine in this group of patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will the investigators develop in The Tropical Medicine Institute Alexander von
      Humboldt that is a referral center in Peru for diseases associated to Human T-Lymphotropic
      Virus 1 Infection (HTLV-1). The Institute has a cohort of around 600 patients currently being
      followed up and around 20 to 25 new patients are admitted every year with this disease.

      This is a pilot study of intervention in a group of patients with tropical spastic
      paraparesis/ myelopathy to evaluate virologic and clinical response of raltegravir plus
      zidovudine in this group of patients on the follow-up of 48 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of proviral load</measure>
    <time_frame>48 weeks</time_frame>
    <description>Evaluate the effect of raltegravir on proviral load , measured as copies/1000 PBMC, in patients with myelopathy of recent onset associated to HTLV-1 at 48 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of Disability Scale</measure>
    <time_frame>48 weeks</time_frame>
    <description>Evaluate the effect of raltegravir on Kurtzke Expanded Disability Status Scale in patients with myelopathy of recent onset associated to HTLV-1 at 48 weeks.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>HTLV-I Infections</condition>
  <condition>Tropical Spastic Paraparesis</condition>
  <arm_group>
    <arm_group_label>HTLV-1 plus Tropical Spastic paraparesis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with recent onset of Tropical Spastic paraparesis due HTLV-1 will receive combination of &quot;Raltegravir&quot; and &quot;Zidovudine&quot; during 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>&quot;Raltegravir&quot; and &quot;Zidovudine&quot;</intervention_name>
    <description>Through measure of pro-viral load and clinical score, we evaluate about safety and efficacy of combination of Raltegravir 400 mg BID and zidovudine 300 mg BID in patients with recent onset of Tropical Spastic paraparesis due HTLV-1 during 48 weeks</description>
    <arm_group_label>HTLV-1 plus Tropical Spastic paraparesis</arm_group_label>
    <other_name>&quot;Raltegravir&quot;</other_name>
    <other_name>&quot;Zidovudine&quot;</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  human t lymphotrophic virus 1 confirmed

          -  Tropical Spastic Paraparesis of recent onset (less than 4 years)

        Exclusion Criteria:

          -  Pregnant or breastfeeding or unwilling to use contraception.

          -  Treatment with immunosuppressive, immunomodulatory or experimental treatments within
             the last 6 months of enrolment in the study.

          -  Patients presenting with medical disorder such as poorly controlled diabetes or
             arterial hypertension, severe cardiac insufficiency, unstable ischemic heart disease,
             abnormal liver function tests (&gt;2.5 times upper limit normal (ULN)) and abnormal
             complete blood count (in particular leukopenia, as defined by a lymphocyte count &lt;500,
             neutrophil &lt;1.5 or platelet count &lt; 100, or thrombocytopenia &lt; 1.5 low limit normal
             (LLN), or any medical condition which, in the opinion of the chief investigator, would
             pose additional risk to the patient.

          -  Presence of human immunodeficiency virus antibodies.

          -  Patients with active hepatitis B or/and C with liver function tests &gt;2.5 times ULN

          -  Exposure to any other investigational drug within 30 days of enrolment in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Gotuzzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Medicina Tropical Alexander von Humboldt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Mejía, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Medicina Tropical Alexander von Humboldt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eduardo Gotuzzo, MD</last_name>
    <phone>51 1 4823910</phone>
    <email>eduardo.gotuzzo@upch.pe</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fernando Mejia, MD</last_name>
    <phone>51 1 4823910</phone>
    <email>fernando.mejia.c@upch.pe</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto de Medicina Tropical Alexander von Humboldt</name>
      <address>
        <city>Lima</city>
        <zip>01</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Gotuzzo, MD</last_name>
      <phone>51 1 4823910</phone>
      <email>eduardo.gotuzzo@upch.pe</email>
    </contact>
    <contact_backup>
      <last_name>Fernando Mejia, MD</last_name>
      <phone>51 1 4823910</phone>
      <email>fernando.mejia.c@upch.pe</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <results_reference>
    <citation>Verdonck K, González E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis. 2007 Apr;7(4):266-81. Review.</citation>
    <PMID>17376384</PMID>
  </results_reference>
  <results_reference>
    <citation>Zurita S, Costa C, Watts D, Indacochea S, Campos P, Sanchez J, Gotuzzo E. Prevalence of human retroviral infection in Quillabamba and Cuzco, Peru: a new endemic area for human T cell lymphotropic virus type 1. Am J Trop Med Hyg. 1997 May;56(5):561-5.</citation>
    <PMID>9180608</PMID>
  </results_reference>
  <results_reference>
    <citation>Primo J, Siqueira I, Nascimento MC, Oliveira MF, Farre L, Carvalho EM, Bittencourt AL. High HTLV-1 proviral load, a marker for HTLV-1 associated myelopathy/tropical spastic paraparesis, is also detected in patients with infective dermatitis associated with HTLV-1. Braz J Med Biol Res. 2009 Aug;42(8):761-4. Epub 2009 Jul 3.</citation>
    <PMID>19578703</PMID>
  </results_reference>
  <results_reference>
    <citation>Izumo S. Neuropathology of HTLV-1-associated myelopathy (HAM/TSP): The 50th Anniversary of Japanese Society of Neuropathology. Neuropathology. 2010 Oct;30(5):480-5. doi: 10.1111/j.1440-1789.2010.01135.x.</citation>
    <PMID>20573027</PMID>
  </results_reference>
  <results_reference>
    <citation>Varrin-Doyer M, Nicolle A, Marignier R, Cavagna S, Benetollo C, Wattel E, Giraudon P. Human T lymphotropic virus type 1 increases T lymphocyte migration by recruiting the cytoskeleton organizer CRMP2. J Immunol. 2012 Feb 1;188(3):1222-33. doi: 10.4049/jimmunol.1101562. Epub 2012 Jan 6.</citation>
    <PMID>22227566</PMID>
  </results_reference>
  <results_reference>
    <citation>Gill PS, Harrington W Jr, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995 Jun 29;332(26):1744-8.</citation>
    <PMID>7760890</PMID>
  </results_reference>
  <results_reference>
    <citation>Hermine O, Allard I, Lévy V, Arnulf B, Gessain A, Bazarbachi A; French ATL therapy group. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J. 2002;3(6):276-82.</citation>
    <PMID>12522449</PMID>
  </results_reference>
  <results_reference>
    <citation>Seegulam ME, Ratner L. Integrase inhibitors effective against human T-cell leukemia virus type 1. Antimicrob Agents Chemother. 2011 May;55(5):2011-7. doi: 10.1128/AAC.01413-10. Epub 2011 Feb 22.</citation>
    <PMID>21343468</PMID>
  </results_reference>
  <results_reference>
    <citation>Treviño A, Parra P, Bar-Magen T, Garrido C, de Mendoza C, Soriano V. Antiviral effect of raltegravir on HTLV-1 carriers. J Antimicrob Chemother. 2012 Jan;67(1):218-21. doi: 10.1093/jac/dkr404. Epub 2011 Sep 29.</citation>
    <PMID>21965433</PMID>
  </results_reference>
  <results_reference>
    <citation>Gotuzzo E, Cabrera J, Deza L, Verdonck K, Vandamme AM, Cairampoma R, Vizcarra D, Cabada M, Narvarte G, De las Casas C. Clinical characteristics of patients in Peru with human T cell lymphotropic virus type 1-associated tropical spastic paraparesis. Clin Infect Dis. 2004 Oct 1;39(7):939-44. Epub 2004 Sep 1.</citation>
    <PMID>15472843</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2015</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Paraparesis</mesh_term>
    <mesh_term>Paraparesis, Spastic</mesh_term>
    <mesh_term>Paraparesis, Tropical Spastic</mesh_term>
    <mesh_term>HTLV-I Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

